Breaking News

Israel Developed COVID-19 Vaccine Enters Phase 3 Study

December 10, 2021 • 11:10 am CST
(Precision Vaccinations News)

 NRx Pharmaceuticals announced on December 9, 2021, the conclusion of high-level meetings in Hungary confirmed the pivotal clinical trial of the BriLife COVID-19 vaccine would soon launch. Regulatory clearance for the BriLife trial is expected by the end of 2021.

The company reported Hungary would be the first European Nation to host a clinical trial site for the registrational phase 2b/3 trial of the BriLife COVID-19 vaccine.

In addition to the already-developed trial protocol, NRx has been invited to submit a pediatric trial protocol that may include injected and nasal spray administration of the COVID-19 vaccine candidate.

"NRx is pleased to partner with Hungary to bring two lifesaving therapies, ZYESAMI and the BriLife COVID-19 vaccine, to people in the Central European region at a time when humanity's war against COVID is far from over," said Prof Jonathan Javitt, MD, MPH Chairman and CEO of NRx, in a press release.

Brilife (VSV ΔG) is a vector-based vaccine that takes VSV and genetically engineers it to express the spike protein of the SARS-CoV-2 betacoronavirus on its envelope.

In addition, the spike protein was replaced with that of SARS-CoV-2, resulting in rapid and potent induction of neutralizing antibodies against the SARS-CoV-2 coronavirus. 

BriLife presents the entire spike protein complex of the coronavirus to the body's immune system and can simultaneously present multiple variants of the spike protein. 

NRx was awarded worldwide development and commercialization rights to the BriLife vaccine on behalf of Israel's Institute for Biological Research.

Medical Review by

Our Trust Standards: Medical Advisory Committee

Share